Merck Awarded Second U.S. Patent for CRISPR Gene-Editing Technology

comunicati

Merck Awarded Second U.S. Patent for CRISPR Gene-Editing Technology

07.04.2020 - 14:45

0

- CRISPR-chrom technology improves access to genome for more efficient editing

- Only U.S. patent holder in the CRISPR chromatin space

- Company driving innovation in CRISPR gene-editing technologies

DARMSTADT, Germany, April 7, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the United States Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. With this allowance, Merck is the only provider with a patent covering the fusion of chromatin modulating peptides to CRISPR proteins, helping to clear chromatin out of the way, increasing access to the genome.

"This award marks our second U.S. CRISPR patent and our 23rd CRISPR-related patent worldwide, and as a leading innovator of CRISPR technology, we will continue to drive innovation and collaborate with scientists around the world to ensure that they have the most advanced gene-editing options," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. 

Because genomic DNA in mammalian cells is wrapped tightly in protein complexes called chromatin, the genomic DNA is often inaccessible to CRISPR. Merck's CRISPR-chrom technology works by fusing chromatin modulating peptides to a CRISPR protein, Cas9 (i.e., CRISPR's DNA scissors), allowing for more efficient gene editing. This work was initially published in the February 2018 issue of The CRISPR Journal and was one of the journal's top five downloaded articles of the year.

The Life Science business of Merck, a leader in genome editing, conducts research and development to drive improvements in gene-editing technologies.

The company's CRISPR patent portfolio includes granted patents for CRISPR-related technologies covering foundational and alternative genome-editing methods. Patents for the company's CRISPR integration technology have been granted in Australia, Canada, China, Europe, Israel, Singapore and South Korea. Patents granted in Europe and pending elsewhere cover plasmid or viral vectors encoding CRISPR systems, which are necessary to perform genome modification in eukaryotic cells. Other European patents and pending applications are for protein-RNA nickase compositions.

Merck received its first U.S. patent in February 2019 for its proxy-CRISPR technology, which makes CRISPR more efficient, flexible and specific. The company has successfully out-licensed its CRISPR patent portfolio and continues to license its entire CRISPR patent portfolio for all fields of use. Merck is proactively and aggressively pursuing CRISPR patent out-licensing partners for therapeutics, agriculture and research and welcome such collaboration opportunities.

CRISPR technology is a core competency for Merck, which has 16 years' experience with genome editing, spanning from discovery to manufacturing. The company develops technologies in a range of genome-editing applications, including gene knockout, gene integration and CRISPR libraries for genetic screens, among others.

Merck recognizes that genome editing has resulted in major advancements in biological research and medicine. At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. The company supports research with genome editing under careful consideration of ethical and legal standards. Merck has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.

All Merck news releases are distributed by email at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About MerckMerck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.

Photo - https://mma.prnewswire.com/media/1141070/Merck.jpg

Condividi le tue opinioni su Corriere dell'Umbria

Caratteri rimanenti: 400

Più letti oggi

Mediagallery

Dl scuola, via libera della Camera: 245 sì e 122 no

Dl scuola, via libera della Camera: 245 sì e 122 no

Roma, 6 giu. (askanews) - L'aula della Camera ha dato il via libera definitivo al decreto scuola con 245 sì e 122 contrari. Concorso per l'assunzione degli insegnanti precari con una prova scritta, da tenersi in autunno, e comunque quando la situazione epidemiologica lo permetterà, ritorno dei giudizi al posto dei voti nella scuola primaria, maggiori tutele per gli alunni con disabilità, poteri ...

 
Il brivido di guidare la Lamborghini Huracan della polizia, il video a 360 gradi

Il brivido di guidare la Lamborghini Huracan della polizia, il video a 360 gradi

(Agenzia Vista) Roma, 06 giugno 2020 Il brivido di guidare la Lamborghini Huracan della polizia, il video a 360 gradi Il filmato pubblicato sui canali social della Polizia di Stato per condurre virtualmente la fuoriserie utilizzata per i trasporti urgenti di organi o sangue. / Polizia di Sato Facebook Fonte: Agenzia Vista / Alexander Jakhnagiev

 
A Madrid riapre il Museo del Prado, applausi dei turisti

A Madrid riapre il Museo del Prado, applausi dei turisti

Roma, 6 giu. (askanews) - Dopo quasi tre mesi di chiusura a causa della pandemia da coronavirus, il museo del Prado di Madrid riapre le sue porte, a un numero limitato di visitatori. Applausi per il momento in cui l'importante museo viene riaperto. Il Prado riapre un'area espositiva equivalente a un quarto del museo. Si accede attraverso la Puerta de Goya e si esce dalla Puerta de Murillo, per ...

 
Ciao Darwin stasera in tv sabato 6 giugno 2020 su Canale 5: la sfida è Belli contro Brutti. Anticipazioni

Televisione

Ciao Darwin stasera in tv sabato 6 giugno 2020 su Canale 5: la sfida è Belli contro Brutti. Anticipazioni

Il programma campione di ascolti in replica torna stasera, sabato 6 giugno 2020, in prima serata su Canale 5. Parliamo dell'atteso appuntamento con la settima edizione ...

06.06.2020

Verissimo, anticipazioni e ospiti di Silvia Toffanin di oggi sabato 6 giugno. Fra Beautiful e videomessaggi

Televisione

Verissimo, anticipazioni e ospiti di Silvia Toffanin di oggi sabato 6 giugno. Fra Beautiful e videomessaggi

Oggi, sabato 6 giugno, 2020 alle ore 16, su Canale 5, nuovo appuntamento con Verissimo – le storie, condotto da Silvia Toffanin. In occasione dei festeggiamenti per i 30 anni ...

06.06.2020

Stasera in tv sabato 6 giugno 2020, "Aspettando le Parole" su Rai3. Anticipazioni e ospiti di Gramellini

Televisione

Stasera in tv sabato 6 giugno 2020, "Aspettando le Parole" su Rai3. Anticipazioni e ospiti di Gramellini

Nuova puntata (è la nona), di Aspettando le Parole, il programma condotto da Massimo Gramellini in onda stasera sabato 6 giugno alle 20.30 su Rai3.   Sarà Matteo Renzi il ...

06.06.2020